ArticleFrontiers in pharmacology2021
Natural Product Erianin Inhibits Bladder Cancer Cell Growth by Inducing Ferroptosis via NRF2 Inactivation.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 99 citations in OpenAlex.
- Article
- Pharmacological activity, molecular mechanisms and therapeutic potential of erianin (Review).International journal of molecular medicine · 2026Review
- Erianin Disturbs Iron and ROS Homeostasis To Trigger Ferroptosis in Colorectal Cancer Cells.Cell biochemistry and biophysics · 2026Article
- Emerging Therapeutic Strategies for Nrf2-Associated Skin Disorders: From Photoaging to Autoimmunity.Antioxidants (Basel, Switzerland) · 2026Review
- Treating T24 cells with erianin restores gefitinib drug sensitivity by regulating MYLK to inhibit EGFR and EMT processes.American journal of cancer research · 2026Article
- Harnessing ferroptosis for cancer therapy: Mechanisms and therapeutic strategies (Review).Oncology reports · 2026Review
- Ferroptosis and cuproptosis in head and neck squamous cell carcinoma: interconnected mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Metformin and Placental Ferroptosis in Gestational Diabetes: A Mechanistic Study.Journal of diabetes research · 2026Article
- The promising arsenal of ferroptosis inducers in bladder cancer.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Exploring Natural Products to Target Ferroptosis in Urologic Malignancies: Advancements from Molecular Mechanisms to Therapeutic Strategies.Chinese journal of integrative medicine · 2025Review
- Advances in Lung Cancer Treatment: Integrating Immunotherapy and Chinese Herbal Medicines to Enhance Immune Response.Chinese journal of integrative medicine · 2025Review
- Erianin induces apoptosis of osteosarcoma cells through ferroptosis signaling pathway, and inhibits proliferation and migration of osteosarcoma cells.Cytotechnology · 2025Article
- Transcription factor TCF3 promotes bladder cancer development via TMBIM6-CaCell death discovery · 2025Article
- Baicalin plays a protective role by regulating ferroptosis in multiple diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Targeting the cholinergic anti-inflammatory pathway: an innovative strategy for treating diseases.Molecular biology reports · 2025Review
- N-Acetylcysteine Alleviates Necrotizing Enterocolitis by Depressing SESN2 Expression to Inhibit Ferroptosis in Intestinal Epithelial Cells.Inflammation · 2025Article
- Nootkatone inhibits the progression of glioblastoma by activating the ATF4-CHOP-CHAC1 pathway.Molecular medicine (Cambridge, Mass.) · 2025Article
- Natural products targeting ferroptosis in cancer: molecular mechanisms and applications.Frontiers in oncology · 2025Review
- Natural product Erianin: mitigating FOLFOX toxicity and enhancing against colorectal cancer.Frontiers in chemistry · 2025Article
- Erianin Suppresses Pancreatic Cancer Progression by Inducing Cell Cycle Arrest and Ferroptosis.Cancer management and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 2 countries.
Yu XiangSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Xiaying ChenSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Wengang WangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Lijuan ZhaiZhejiang Chinese Medical University, Hangzhou, China.
Xueni SunSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Jiao FengSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Ting DuanSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Mingming ZhangSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Ting PanSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Lili YanSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Ting JinSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Quan GaoSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Chengyong WenSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Weirui MaSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Wencheng LiuSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Deqiang WangDepartment of Medical Oncology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, China.
Qibiao WuState Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
Tian XieSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Xinbing SuiSchool of Pharmacy and Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Hangzhou Normal University · CNAffiliated Hospital of Hangzhou Normal University · CNAffiliated Hospital of Jiangsu University · CNChengdu University of Traditional Chinese Medicine · CNJiangsu University · CNMacau University of Science and Technology · MOZhejiang Chinese Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erianin, a natural product derived from
Indexed as
bladder cancerErianinferroptosisnatural productnuclear factor E2-related factor 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.